{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:01:38Z","timestamp":1790427698237,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.transproceed.2026.06.040","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:09:43Z","timestamp":1788606583000},"page":"1653-1669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multinational Retrospective Chart Review of Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Solid Organ Transplant Recipients With Refractory\/Resistant Cytomegalovirus Infection or Intolerance to Anti-Cytomegalovirus Therapy"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-6170","authenticated-orcid":false,"given":"Emily A.","family":"Blumberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Len","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakila","family":"Rajack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Hirji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2026.06.040_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0002","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0003","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/v16071085","article-title":"Refractory\/resistant cytomegalovirus infection in transplant recipients: an update","volume":"16","author":"Royston","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2023.100804","article-title":"Incidence of refractory CMV infection with or without antiviral resistance in Spain: a systematic literature review","volume":"38","author":"Aguado","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0006","doi-asserted-by":"crossref","first-page":"ofz215","DOI":"10.1093\/ofid\/ofz215","article-title":"Risk factors for failure of primary (val)ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients","volume":"6","author":"Khurana","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0007","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13696998.2022.2046388","article-title":"Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation","volume":"25","author":"Cheng","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0010","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0012","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/591532","article-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","volume":"47","author":"San Juan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0014","unstructured":"Takeda Pharmaceuticals America Inc. Livtencity. Prescribing information.https:\/\/content.takeda.com\/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1 [accessed 13\/05\/2026 2026]."},{"key":"10.1016\/j.transproceed.2026.06.040_bib0015","unstructured":"Takeda Pharmaceuticals International AG Ireland Branch. Livtencity. Summary of product characteristics1. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livtencity-epar-product-information_en.pdf, [accessed 13\/05\/2026 2026]."},{"key":"10.1016\/j.transproceed.2026.06.040_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12881","article-title":"Cytomegalovirus resistance in CD34+-selected hematopoietic cell transplant recipients","volume":"20","author":"Kim","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0017","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.healun.2019.09.005","article-title":"Drug-resistant cytomegalovirus infection after lung transplantation: incidence, characteristics, and clinical outcomes","volume":"38","author":"Heli\u00f6vaara","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0018","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12852","article-title":"Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study","volume":"20","author":"Pierce","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11295","article-title":"Factors associated with genotypic resistance and outcome among solid organ transplant recipients with refractory cytomegalovirus infection","volume":"36","author":"Tamzali","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0023","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0024","doi-asserted-by":"crossref","first-page":"ofad018","DOI":"10.1093\/ofid\/ofad018","article-title":"Cytomegalovirus DNAemia requiring (val)ganciclovir treatment for more than 8 weeks is a key factor in the development of antiviral drug resistance","volume":"10","author":"Acquier","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl. 4)","key":"10.1016\/j.transproceed.2026.06.040_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0026","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jinf.2014.07.001","article-title":"Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients","volume":"69","author":"Mart\u00edn-Gandul","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.transproceed.2026.06.040_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1034\/j.1399-3062.2001.00011.x","article-title":"Multicenter US study of hospital resource utilization associated with cytomegalovirus-related readmission of renal and heart transplant patients","volume":"3","author":"Henderson","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12732","article-title":"Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting","volume":"19","author":"Hakimi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory cmv for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2026.06.040_bib0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526003623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526003623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:49:50Z","timestamp":1790426990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134526003623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0041134526003623"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.06.040","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multinational Retrospective Chart Review of Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Solid Organ Transplant Recipients With Refractory\/Resistant Cytomegalovirus Infection or Intolerance to Anti-Cytomegalovirus Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.06.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Development Center Americas, Inc.. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}